D. Boral Capital Reaffirms Buy Rating for OS Therapies

Analysts maintain positive outlook on biotech firm's prospects

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

D. Boral Capital, an equity research firm, has reissued a "buy" rating and set a $20.00 price target on shares of OS Therapies (NYSEAMERICAN:OSTX), a clinical-stage biopharmaceutical company focused on developing treatments for osteosarcoma and other solid tumors. This comes as several other brokerages have also recently weighed in on the stock, with Zacks Research upgrading OS Therapies from a "strong sell" to a "hold" rating, and Lake Street Capital lowering its price target from $18.00 to $17.00 while maintaining a "buy" rating.

Why it matters

The reaffirmed "buy" rating and price target from D. Boral Capital suggests analysts remain optimistic about OS Therapies' potential, despite some volatility in the stock price. As a clinical-stage biotech company, OS Therapies' progress in developing novel treatments for osteosarcoma and other cancers is closely watched by investors seeking exposure to promising therapeutic pipelines.

The details

D. Boral Capital's research note on OS Therapies cited the company's ongoing clinical trials and development of its pipeline, including the OST-HER2 off-the-shelf immunotherapy and the OST-tunable drug conjugate (OST-tADC) technology. The analysts believe these programs hold promise and warrant the "buy" rating and $20.00 price target, even as other firms have made minor adjustments to their own price targets for the stock.

  • On Monday, March 9, 2026, D. Boral Capital reissued its "buy" rating and $20.00 price target on OS Therapies.
  • In November 2025, Zacks Research upgraded OS Therapies from a "strong sell" to a "hold" rating.
  • Also in November 2025, Lake Street Capital lowered its price target on OS Therapies from $18.00 to $17.00, while maintaining a "buy" rating.

The players

D. Boral Capital

An equity research firm that covers OS Therapies and has reaffirmed a "buy" rating on the stock.

OS Therapies

A clinical-stage biopharmaceutical company focused on developing treatments for osteosarcoma and other solid tumors.

Zacks Research

An equity research firm that recently upgraded its rating on OS Therapies from "strong sell" to "hold".

Lake Street Capital

An equity research firm that lowered its price target on OS Therapies from $18.00 to $17.00 while maintaining a "buy" rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

This reaffirmed "buy" rating from D. Boral Capital underscores the ongoing investor interest and optimism surrounding OS Therapies' pipeline of potential osteosarcoma and solid tumor treatments, despite some recent volatility in the stock price. As a clinical-stage biotech, OS Therapies' progress will continue to be closely watched by the investment community.